AbbVie's Botox Cosmetic has cleared another regulatory hurdle in its path to FDA approval for masseter prominence—the first neurotoxin indication for jawline reduction. If approved, Botox would be the first and only toxin cleared for this use, creating a new category within the aesthetic toxin market and a potential revenue stream independent of migraine, spasticity, and hyperhidrosis applications.
Regulatory
Botox Masseter Indication Moves Closer to FDA OK
AbbVie advances toward first-ever neurotoxin approval for jawline contouring.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
If approved, Botox would be the first and only neurotoxin for masseter prominence.
The masseter indication targets a growing segment of patients seeking non-surgical jawline definition, particularly in younger demographics. For practices, approval would expand the toxin conversation beyond forehead, brow, and crow's feet, adding a procedural option that complements filler and RF microneedling jawline treatments. The competitive landscape would shift: Jeuveau and other toxins would need their own sBLAs to match the indication.
Source: original report ↗
Frequently asked questions
What is Botox masseter indication and how does it work?
Botox masseter indication targets the masseter muscle—the muscle responsible for jaw clenching—to reduce its prominence and create a slimmer jawline. When injected into the masseter, Botox relaxes the muscle, causing it to atrophy over time and resulting in visible jawline contouring without surgery.
Is Botox approved for jawline contouring yet?
As of now, Botox Cosmetic has cleared another regulatory hurdle but is not yet FDA-approved for masseter prominence. AbbVie is advancing toward first-ever neurotoxin approval for this indication, but final FDA clearance has not been granted.
Will other Botox alternatives like Jeuveau be approved for masseter?
If Botox receives FDA approval for masseter, competitors like Jeuveau would need to file their own supplemental Biologics License Applications (sBLAs) to gain the same indication. Currently, no neurotoxin has this approval.
What patient demographics are interested in masseter Botox?
The masseter indication targets a growing segment seeking non-surgical jawline definition, with particularly strong interest among younger demographics looking for facial contouring without invasive procedures.
How does masseter Botox complement other jawline treatments?
Masseter Botox would work alongside existing jawline treatments like dermal fillers and RF microneedling to offer practices a multi-modal approach to jawline definition. This expands the treatment conversation beyond traditional toxin uses like forehead and crow's feet.
What would be the business impact of Botox masseter approval?
Approval would create a new category within the aesthetic toxin market and establish a potential revenue stream independent of Botox's existing migraine, spasticity, and hyperhidrosis applications, giving practices a differentiated service offering.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.